Physician profile
Thomas Hargest
NPI 1528082930
$12,879.81
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,821 · 2020: $1,308 · 2021: $2,370 · 2022: $2,495 · 2023: $2,813 · 2024: $2,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,880 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,879.95 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,043.17 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,861.05 | 2021-2024 | |
| Pfizer INC. | $1,212.19 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,192.32 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,160.40 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $1,030.43 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $741.74 | 2019-2024 | Jardiance, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.75 | 2021-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $396.51 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Amarin Pharma, INC. | $306.44 | 2019-2021 | |
| Amgen INC. | $207.53 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $198.61 | 2020 | |
| Esperion Therapeutics, INC. | $197.55 | 2021-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $182.25 | 2019-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $181.59 | 2021-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hargest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.